Literature DB >> 9605956

Long-term prognosis of non-shunt operation for idiopathic portal hypertension.

K Ohashi1, K Kojima, M Fukazawa, T Beppu, S Futagawa.   

Abstract

This report presents 46 Japanese patients with idiopathic portal hypertension (IPH) in whom non-shunt operation was performed for the management of esophageal varices. Non-shunt operation included transthoracic esophageal transection (Sugiura's procedure) in 37 patients, transabdominal esophageal transection (TAET) in 3 patients, and Hassab's procedure in 6 patients. Rates of postoperative variceal eradication were: 78.4% by Sugiura's procedure; 100% by TAET; and 50% by Hassab's procedure. The cumulative rates for recurrent varices and recurrent bleeding were 3.9%, and 5.1%, respectively, at 5 years, and 8.9% and 9.8% at both 10 and 15 years. Only 3 patients required additional endoscopic injection sclerotherapy to treat recurrent varices. Although 3 patients developed upper gastrointestinal bleeding, the source of hemorrhage was esophageal varices in 1, and portal hypertensive gastropathy in 2; none of the patients died from bleeding. Actuarial survival for all patients was 87.5% at 5 years, 77.9% at 10 years, and 58.8% at 15 years. There were no deaths within the first 30 days after surgery. These results show that non-shunt operation is useful in preventing bleeding from esophageal varices in patients with IPH.

Entities:  

Mesh:

Year:  1998        PMID: 9605956     DOI: 10.1007/s005350050077

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  2 in total

1.  New operative method for fundal variceal bleeding: fundectomy with periesophagogastric devascularization.

Authors:  Ho-Seong Han; Nam-Joon Yi; Young-Woo Kim; Gary D Fleischer
Journal:  World J Surg       Date:  2004-03-04       Impact factor: 3.352

2.  Japanese periodical nationwide epidemiologic survey of aberrant portal hemodynamics.

Authors:  Satoko Ohfuji; Yoshihiro Furuichi; Tomohiko Akahoshi; Masayoshi Kage; Katsutoshi Obara; Makoto Hashizume; Tomoka Matsuura; Wakaba Fukushima; Yosikazu Nakamura
Journal:  Hepatol Res       Date:  2019-04-25       Impact factor: 4.288

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.